Concepedia

Andrew O. Yam

AO

Statistics

Publications

10

Citations

512

H-Index

10

Active since

2003

Affiliations

Garvan Institute of Medical Research(Current)

UNSW Sydney

St Vincent's Clinic

The University of Sydney

The Kinghorn Cancer Centre

Andrew O. Yam is an author at Garvan Institute of Medical Research specializing in medicine, cancer therapeutics, and oncology.

ORCID

Top concepts

Publications per year

2003–2023

10

Publications

10

Nuclear Factor-κB Regulates β-Cell Death

David Liuwantara, Mark Elliot, Mariya W. Smith et al. · Diabetes · 2006 · 112 citations · Full text

, , +20

Modification of In Vivo and In Vitro T- and B-Cell-Mediated Immune Responses by the<i>Pseudomonas aeruginosa</i>Quorum-Sensing Molecule<i>N</i>-(3-Oxododecanoyl)-<scp>l</scp>-Homoserine Lactone

Adam Ritchie, Andrew O. Yam, Kara M. Tanabe et al. · Infection and Immunity · 2003 · 103 citations · Full text

<sup>177</sup>Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing<sup>177</sup>Lu-PSMA-I&amp;T Therapy

Nikeith John, Sarennya Pathmanandavel, Megan Crumbaker et al. · Journal of Nuclear Medicine · 2022 · 59 citations · Full text

Evaluation of<sup>177</sup>Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective<sup>177</sup>Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)

Sarennya Pathmanandavel, Megan Crumbaker, Bao Ho et al. · Journal of Nuclear Medicine · 2022 · 51 citations · Full text

, , +26

<sup>177</sup>Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial

Sarennya Pathmanandavel, Megan Crumbaker, Andrew O. Yam et al. · Journal of Nuclear Medicine · 2021 · 43 citations · Full text

1–5 of 10